TY - JOUR
T1 - Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine
AU - Wintsch, Joelle
AU - Chaignat, Claire Lise
AU - Braun, Dietmar G.
AU - Jeannet, Michel
AU - Stalder, Hans
AU - Abrignani, Sergio
AU - Montagna, Daniela
AU - Clavijo, Freddy
AU - Moret, Philippe
AU - Dayer, Jean Michel
AU - Staehelin, Theophil
AU - Doe, Barbara
AU - Steimer, Kathelyn S.
AU - Dina, Dino
AU - Cruchaud, Andre
PY - 1991
Y1 - 1991
N2 - A phase 1 trial of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine was done in 25 healthy seronegative subjects. The antigen, env2-3 (SF2), was a nonglycosylated polypeptide representing the gp120 region of the env gene of the HIV-l(SF2) isolate. It was produced in genetically engineered yeast as a denatured molecule incapable of binding CD4. A synthetic lipophilic muramyl tripeptide (MTP-PE) was used as an adjuvant. Ten subjects received adjuvant alone and 15 received 50- or 25O-JLg doses of env2-3 (SF2) administered intramuscularly in two immunization regimens. In general, adjuvant and vaccine were well tolerated. Antibody responses to both the homologous antigen, env2-3 (SF2), and antigens from other highly divergent HIV isolates were elicited in the majority of vaccine recipients. However, antibody titers were low, without neutralizing activity. In 9 of 11 subjects who received the complete vaccine immunization series, a significant specific T lymphocyte response was observed.
AB - A phase 1 trial of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine was done in 25 healthy seronegative subjects. The antigen, env2-3 (SF2), was a nonglycosylated polypeptide representing the gp120 region of the env gene of the HIV-l(SF2) isolate. It was produced in genetically engineered yeast as a denatured molecule incapable of binding CD4. A synthetic lipophilic muramyl tripeptide (MTP-PE) was used as an adjuvant. Ten subjects received adjuvant alone and 15 received 50- or 25O-JLg doses of env2-3 (SF2) administered intramuscularly in two immunization regimens. In general, adjuvant and vaccine were well tolerated. Antibody responses to both the homologous antigen, env2-3 (SF2), and antigens from other highly divergent HIV isolates were elicited in the majority of vaccine recipients. However, antibody titers were low, without neutralizing activity. In 9 of 11 subjects who received the complete vaccine immunization series, a significant specific T lymphocyte response was observed.
UR - http://www.scopus.com/inward/record.url?scp=0026023163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026023163&partnerID=8YFLogxK
U2 - 10.1093/infdis/163.2.219
DO - 10.1093/infdis/163.2.219
M3 - Article
C2 - 1988506
AN - SCOPUS:0026023163
VL - 163
SP - 219
EP - 225
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 2
ER -